• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

    4/21/25 4:05:00 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEON alert in real time by email

    IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today the appointment of Rob Bancroft as President and Chief Executive Officer, effective April 29, 2025. Mr. Bancroft will also join AEON's Board of Directors.

    "We are excited to welcome Rob as the new President and Chief Executive Officer of AEON. He is an exceptional leader who brings a wealth of experience in the therapeutic toxin industry, and a strong track record of building value through the execution of well-defined strategies," commented Mr. Jost Fischer, Chairman of the AEON Board and Interim President and Chief Executive Officer. "Rob is uniquely positioned to hit the ground running and lead the rest of the AEON team as we continue to advance our ABP-450 program along the planned 351(k) biosimilar regulatory pathway. We believe this strategy could bring ABP-450 to the U.S. market for all of BOTOX's currently approved and future therapeutic indications under a single FDA approval."

    "I am excited to join the AEON team and work towards delivering on ABP-450's tremendous potential as a biosimilar that shares the exact same 900kDa molecular weight as BOTOX. If approved, we believe ABP-450 could offer a scientifically validated and clinically comparable alternative to BOTOX, creating additional choice for physicians, helping expand access to care for patients who face cost-related barriers, and supporting broader system affordability," stated Mr. Bancroft. "We are looking forward to announcing the results of our Biosimilar BPD Type 2a meeting with the FDA, which is anticipated in the second half of 2025, and next steps in the development program for ABP-450."

    Mr. Bancroft brings over 25 years of leadership experience in the life sciences industry, spanning biopharmaceuticals, medical devices, and healthcare technology. Prior to joining AEON, he served as General Manager of the Therapeutics business at Revance Therapeutics, where he led the launch of Daxxify® in cervical dystonia with a novel strategy that prioritized expert endorsement, payer coverage, and reimbursement infrastructure ahead of broader investment - driving strong early adoption and differentiated positioning in the $3B botulinum toxin therapeutics market. Previously, Mr. Bancroft was President of Smith & Nephew's Biotherapeutics division, following the $782M acquisition of Healthpoint Biotherapeutics, where he orchestrated a strategic turnaround that led to four consecutive years of accelerating growth. He also served as Chief Executive Officer of QMENTA, a neuroimaging SaaS startup, where he guided the company through the COVID-19 pandemic and led a successful post-seed funding round. Earlier in his career, Mr. Bancroft held senior leadership roles at Allergan, where he was responsible for global strategy and U.S. commercialization of BOTOX® in multiple therapeutic indications. Mr. Bancroft earned his B.S. in Biology from Indiana University and his M.B.A. from the University of Southern California.

    About AEON Biopharma

    AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit www.aeonbiopharma.com.

    Forward-Looking Statements

    Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or AEON's future financial or operating performance. For example, statements regarding meetings with the FDA, the timing of primary comparative analytical studies, and potential determination that ABP-450 is highly similar to the reference product for currently approved and future therapeutic indications are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "plan", "possible", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential", "continue" or "could", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

    These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by AEON and its management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the outcome of any legal proceedings that may be instituted against AEON or others; (ii) AEON's future capital requirements; (iii) AEON's ability to raise financing in the future; (iv) AEON's ability to maintain the cash balance required to work through our Biosimilar BPD Type 2a meeting with the FDA; (v) AEON's ability to continue to meet continued stock exchange listing standards; (vi) the possibility that AEON may be adversely affected by other economic, business, regulatory, and/or competitive factors; (vii) AEON's ability to progress along a 351(k) biosimiliar pathway to allow ABP-450 to be approved as a biosimilar to BOTOX under a single FDA approval; (viii) the outcomes from any meetings or discussions with regulatory authorities; and (ix) other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Company's filings with the Securities and Exchange Commission (the "SEC"), which are available on the SEC's website at www.sec.gov.

    Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. AEON does not undertake any duty to update these forward-looking statements.

    Contacts

    Investor Contact:

    Corey Davis, Ph.D.

    LifeSci Advisors

    +1 212 915 2577

    [email protected]

    Source: AEON Biopharma



    Primary Logo

    Get the next $AEON alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AEON

    DatePrice TargetRatingAnalyst
    8/18/2023$18.00Buy
    H.C. Wainwright
    More analyst ratings

    $AEON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Thunen Shelley B

      4 - AEON Biopharma, Inc. (0001837607) (Issuer)

      5/23/25 5:04:47 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Exec VP, CLO & Corp Secretary Wilson Alexander Blair

      4 - AEON Biopharma, Inc. (0001837607) (Issuer)

      5/23/25 4:57:12 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Oh Chad

      4 - AEON Biopharma, Inc. (0001837607) (Issuer)

      5/23/25 4:56:33 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

      IRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today reported the grant in May of 102,880 restricted stock units (RSUs) of the Company's common stock to newly hired non-executive employees of the company. The awards were approved by the Company's Board of Directors under the AEON 2025 Inducement Incentive Plan, which a grant date and vesting commencement date of May 21, 2025. The RSUs vest over four years, 25% on each annual anniversary of the vesting commencement date. The awards are

      5/23/25 4:05:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

      IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Rob Bancroft, AEON's President and Chief Executive Officer, will present a corporate overview at the Aegis Capital Corp. 2025 Virtual Conference on Wednesday, May 21st at 7:00 a.m. PT / 10:00 am ET. Please register here to attend the conference on Wednesday, May 21st. About AEON Biopharma AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabot

      5/19/25 4:05:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

      – Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for ABP-450, which offers potential access to the U.S. market under a single approval for all of BOTOX's currently approved and future therapeutic indications – – Appointed Rob Bancroft as the Company's President and Chief Executive Officer; Mr. Bancroft also joined AEON's Board of Directors – IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum

      5/14/25 4:05:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEON
    SEC Filings

    See more
    • SEC Form 424B5 filed by AEON Biopharma Inc.

      424B5 - AEON Biopharma, Inc. (0001837607) (Filer)

      6/16/25 4:02:09 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AEON Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - AEON Biopharma, Inc. (0001837607) (Filer)

      6/13/25 4:05:17 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-Q/A filed by AEON Biopharma Inc.

      10-Q/A - AEON Biopharma, Inc. (0001837607) (Filer)

      6/11/25 4:06:45 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fischer Jost bought $29,250 worth of shares (60,000 units at $0.49), increasing direct ownership by 29% to 266,785 units (SEC Form 4)

      4 - AEON Biopharma, Inc. (0001837607) (Issuer)

      5/23/25 4:46:16 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fischer Jost bought $55,300 worth of shares (110,000 units at $0.50), increasing direct ownership by 114% to 206,785 units (SEC Form 4)

      4 - AEON Biopharma, Inc. (0001837607) (Issuer)

      5/21/25 4:50:20 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on AEON Biopharma with a new price target

      H.C. Wainwright initiated coverage of AEON Biopharma with a rating of Buy and set a new price target of $18.00

      8/18/23 8:03:13 AM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEON
    Leadership Updates

    Live Leadership Updates

    See more
    • AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

      IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that, in connection with the appointment of Rob Bancroft as President and Chief Executive Officer, the Company's Compensation Committee of the Board of Directors has approved the grant of inducement awards. The Compensation Committee approved the grant to Mr. Bancroft of a non-qualified stock option to purchase 59,034 shares of AEON Class A common stock under AEON's 2025 Employment Inducement Incentive Award Plan (the "I

      4/21/25 4:10:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

      IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today the appointment of Rob Bancroft as President and Chief Executive Officer, effective April 29, 2025. Mr. Bancroft will also join AEON's Board of Directors. "We are excited to welcome Rob as the new President and Chief Executive Officer of AEON. He is an exceptional leader who brings a wealth of experience in the therapeutic toxin industry, and a strong track record of building value through the execution of well-defined s

      4/21/25 4:05:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AEON Biopharma Announces CEO Transition

      – Marc Forth Steps Down as President and CEO to Pursue Another Opportunity; will remain on the Board of Directors – – Jost Fischer, Chairman of AEON, will assume the role of interim CEO – IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today a leadership transition under which Marc Forth is stepping down as President and Chief Executive Officer of the Company to pursue another opportunity, effective April 4, 2025. Mr. Forth will continue with the Company as a member of it

      3/27/25 4:05:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEON
    Financials

    Live finance-specific insights

    See more
    • AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

      – Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for ABP-450, which offers potential access to the U.S. market under a single approval for all of BOTOX's currently approved and future therapeutic indications – – Appointed Rob Bancroft as the Company's President and Chief Executive Officer; Mr. Bancroft also joined AEON's Board of Directors – IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum

      5/14/25 4:05:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

      – ABP-450 doses of 150 units and 195 units showed treatment effect of 4.8 days and 5.0 days, respectively, in the mean change from baseline in monthly migraine days (MMD) at weeks 21-24 but did not meet statistical significance vs. placebo because of a much higher-than-expected placebo response of 4.2 days – – Study demonstrated statistical significance on multiple secondary and exploratory endpoints, including the responder analysis of both a >50% and >75% improvement from baseline in MMD – – Totality of the data showed evidence of a dose response favoring the higher 195 units arm, and supports the decision to advance into Phase 3, anticipated in 2H 2024 – – Ongoing Phase 2 trial for the

      10/19/23 4:05:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by AEON Biopharma Inc.

      SC 13G - AEON Biopharma, Inc. (0001837607) (Subject)

      11/14/24 5:05:14 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care